Methods to assess population effectiveness of therapies in human immunodeficiency virus incident and prevalent cohorts

American Journal of Epidemiology

Volumn 154, Issue 7, 2001, Pages 675-681

  Tarwater, Patrick M ^a   Mellors, John ^b   Gore, Mary E ^a   Margolick, Joseph B ^a   Phair, John ^c   Detels, Roger ^d   Muñoz, Alvaro ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Acquired immunodeficiency syndrome; Cohort studies; Epidemiologic methods; HIV

Indexed keywords

ANTIRETROVIRUS AGENT; NUCLEOSIDE; VIRUS RNA;

COHORT ANALYSIS; DISEASE TREATMENT; HUMAN IMMUNODEFICIENCY VIRUS;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; DISEASE DURATION; FOLLOW UP; HEALTH HAZARD; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PROGNOSIS; SEROPREVALENCE; TECHNIQUE; TREATMENT OUTCOME;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTI-HIV AGENTS; BIOLOGICAL MARKERS; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; DISEASE PROGRESSION; EPIDEMIOLOGIC METHODS; HIV; HIV INFECTIONS; HUMANS; MALE; PROGNOSIS; RISK FACTORS; RNA, VIRAL; SEROEPIDEMIOLOGIC STUDIES; TREATMENT OUTCOME;

EID: 0035479131     PISSN: 00029262     EISSN: None     Source Type: Journal    
DOI: 10.1093/aje/154.7.675     Document Type: Article

References (32)

1. Epidemiologic analyses of causation: The unlearned scientific lessons of randomized trials
2. Randomized, controlled trials, observational studies, and the hierarchy of research designs
3. A comparison of observational studies and randomized, controlled trials
4. Distinguishing efficacy, individual effectiveness, and population effectiveness of therapies
5. Use of cohort studies for evaluating AIDS therapies
6. Assessing the impact of highly active antiretroviral therapy on AIDS and death
7. Use of observational data for evaluating AIDS therapies
8. + T-cell counts in HIV-infected patients
9. Treatment with indinavir, zidovudine, and lamivudine in adults with immunodeficiency virus infection and prior antiretroviral therapy
10. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less
11. Effect of zidovudine and Pneumocystis carinii pneumonia prophylaxis on progression of HIV-1 infection to AIDS
12. Effect of routine use of therapy in slowing the clinical course of human immunodeficiency virus (HIV) infection in a population-based cohort
13. Use of observational databases to evaluate the effectiveness of antiretroviral therapy for HIV infection: Comparison of cohort studies with randomized trials
14. Decline in deaths from AIDS due to new antiretrovirals
15. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration
16. Temporal trends in the progression of human immunodeficiency virus disease in a cohort of drug users
17. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
18. Models of survival in HIV infection and their use in the qualification of treatment benefits
19. Improved survival among HIV-infected individuals following initiation therapy
20. The effectiveness of interventions on incubation of AIDS as measured by secular increases within a population
21. Effectiveness of potent antiretroviral therapy on the incidence of opportunistic infections before and after AIDS diagnosis
22. Survival after introduction of HAART in people with known duration of HIV-1 infection
23. Temporal changes in the rate of progression to death among Italians with known date of HIV seroconversion: Estimates of the population effect of treatment. Italian HIV Seroconversion Study
24. Estimating AIDS-free survival in a severely immunosuppresed asymptomatic HIV-infected population in the era of antiretroviral triple combination therapy
25. An introduction to instrumental variables for epidemiologists
26. Left-truncated data with age as time scale: An alternative for survival analysis in the elderly population
27. Effects of anticoagulant, processing delay, and assay method (branched DNA versus reverse transcriptase PCR) on measurement of human immunodeficiency virus type-1 RNA levels in plasma
28. Time from HIV-1 seroconversion to AIDS and death before widespread use of highly active antiretroviral therapy: A collaborative re-analysis
29. Acquired immunodeficiency syndrome (AIDS) risk in recent and long-standing human immunodeficiency virus type-1 (HIV-1) infected patients with similar CD4 lymphocyte counts
30. CD4 lymphocyte count as a determinant of the time from HIV seroconversion to AIDS and death from AIDS: Evidence from the Italian Seroconversion Study
31. Replacing time since human immunodeficiency virus infection by marker values in predicting residual time to acquired immunodeficiency syndrome diagnosis
32. Evaluation of the effect of time from seroconversion on AIDS: Results from CASCADE (Concerted Action on Sero Conversion to AIDS and Death in Europe)